Guidelines for the Evaluation and Management of Heart Failure
John F. Williams(University of Florida), Thomas J. Ryan(Jacobs (United States)), Raymond J. Gibbons(Mayo Clinic), Milton Packer(Baylor University Medical Center), Michael R. Bristow(University of Colorado Health), Bertram Pitt(Bayer (Germany)), LAURA F. WEXLER, Bernard J. Gersh(Clinical Research Institute), Richard P. Lewis, Kim A. Eagle(University of Michigan), Daniel J. Ullyot, James L. Ritchie(Facing Our Risk of Cancer Empowered), Timothy J. Gardner(Christiana Care Health System), Melvin D. Cheitlin(San Francisco General Hospital), Michael B. Fowler(Michael & Associates), Gary S. Francis, Robert A. O’Rourke(Richard Wolf (Germany)), William L. Winters, Mark A. Hlatky(Cardiovascular Institute of the South), Carl V. Leier(The Ohio State University), Donald Hammer
Cited by 668
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies
|Circulation|1996|3.5k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k